thalidomide has been researched along with Dizzyness in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the efficacy of thalidomide in suppressing cough in patients with IPF." | 9.16 | Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. ( Danoff, SK; Horton, KM; Horton, MR; Lechtzin, N; Liu, MC; Mathew, L; Polito, AJ; Santopietro, V, 2012) |
| "To investigate the efficacy and toxicity of bortezomib based combination therapy for Chinese patients with relapsed or refractory multiple myeloma (MM), and to determine the combination regimen, dosage and cycles in application of bortezomib for MM therapy." | 9.13 | [Bortezomib-based combination therapy for relapsed or refractory multiple myeloma]. ( Chen, YB; Fu, WJ; Hou, J; Wang, DX; Xi, H; Yuan, ZG, 2008) |
| "13 patients with treatment-resistant multiple myeloma with advanced osteolytic lesions received combined pamidronate and thalidomide therapy." | 9.10 | Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. ( Baran, W; Ciepłuch, H; Hellmann, A, 2002) |
| "The aim of this study was to define prognostic factors that might be predictive for response to thalidomide (Thal) in progressive multiple myeloma (n = 54)." | 9.09 | High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. ( Benner, A; Egerer, G; Goldschmidt, H; Hillengass, J; Ho, AD; Kraemer, A; Moehler, T; Neben, K, 2001) |
| "To determine the efficacy of thalidomide in suppressing cough in patients with IPF." | 5.16 | Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. ( Danoff, SK; Horton, KM; Horton, MR; Lechtzin, N; Liu, MC; Mathew, L; Polito, AJ; Santopietro, V, 2012) |
| "To investigate the efficacy and toxicity of bortezomib based combination therapy for Chinese patients with relapsed or refractory multiple myeloma (MM), and to determine the combination regimen, dosage and cycles in application of bortezomib for MM therapy." | 5.13 | [Bortezomib-based combination therapy for relapsed or refractory multiple myeloma]. ( Chen, YB; Fu, WJ; Hou, J; Wang, DX; Xi, H; Yuan, ZG, 2008) |
| "13 patients with treatment-resistant multiple myeloma with advanced osteolytic lesions received combined pamidronate and thalidomide therapy." | 5.10 | Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. ( Baran, W; Ciepłuch, H; Hellmann, A, 2002) |
| "The aim of this study was to define prognostic factors that might be predictive for response to thalidomide (Thal) in progressive multiple myeloma (n = 54)." | 5.09 | High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. ( Benner, A; Egerer, G; Goldschmidt, H; Hillengass, J; Ho, AD; Kraemer, A; Moehler, T; Neben, K, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yuan, ZG | 1 |
| Hou, J | 1 |
| Wang, DX | 1 |
| Fu, WJ | 1 |
| Chen, YB | 1 |
| Xi, H | 1 |
| Horton, MR | 1 |
| Santopietro, V | 1 |
| Mathew, L | 1 |
| Horton, KM | 1 |
| Polito, AJ | 1 |
| Liu, MC | 1 |
| Danoff, SK | 1 |
| Lechtzin, N | 1 |
| Neben, K | 1 |
| Moehler, T | 1 |
| Egerer, G | 1 |
| Kraemer, A | 1 |
| Hillengass, J | 1 |
| Benner, A | 1 |
| Ho, AD | 1 |
| Goldschmidt, H | 1 |
| Ciepłuch, H | 1 |
| Baran, W | 1 |
| Hellmann, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide[NCT00600028] | Phase 3 | 25 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary endpoint, suppression of cough was measured by the Cough Quality of Life Questionnaire (CQLQ) to measure the effect of interventions on cough-specific quality of life.~CQLQ consist of 28 questions about cough and its effects using Likert-like 4-point scales, with lower scores indicating less effect of cough on health related quality of life.~CQLQ scale ranges from 28 to 112 ( The lower the value, the higher the quality of life, 28 is considered the best)." (NCT00600028)
Timeframe: 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Arm Thalidomide 1st, Placebo 2nd (Intervention Thalidomide) | 47.3 |
| Arm Thalidomide 1st, Placebo 2nd (Intervention Placebo) | 55.2 |
| Arm Placebo 1st, Thalidomide 2nd (Intervention Placebo) | 61.6 |
| Arm Placebo 1st, Thalidomide 2nd (Intervention Thalidomide) | 44.5 |
"The secondary endpoint, suppression of cough was measured by the visual analog scale of cough (VAS) was significantly lower during treatment with thalidomide than placebo.~Secondary endpoints were Cough VAS - the visual analog scale of cough evaluates the severity of cough in patients with IPF.~Visual analog scale of cough ranges from 0 to 100 (0 is considered the best).~St. George Respiratory Questionnaire helps to evaluate cough-specific and respiratory quality of life in patients with IPF.~St. George Respiratory Questionnaire score ranges from 0 to 100 (0 is considered the best)." (NCT00600028)
Timeframe: 6 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Severity of cough (VAS Score) | Quality of life (SGRQ Score) | |
| Arm Placebo 1st, Thalidomide 2nd (Intervention Placebo) | 68 | 58.8 |
| Arm Placebo 1st, Thalidomide 2nd (Intervention Thalidomide) | 17.8 | 40.7 |
| Arm Thalidomide 1st, Placebo 2nd (Intervention Placebo) | 65.9 | 54.7 |
| Arm Thalidomide 1st, Placebo 2nd (Intervention Thalidomide) | 30.3 | 46.4 |
4 trials available for thalidomide and Dizzyness
| Article | Year |
|---|---|
[Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2008 |
Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial.
Topics: Aged; Antitussive Agents; Constipation; Cough; Dizziness; Double-Blind Method; Female; Humans; Idiop | 2012 |
High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
Topics: Adult; Affect; Aged; Angiogenesis Inhibitors; Constipation; Dizziness; Dose-Response Relationship, D | 2001 |
Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2002 |